FDA Clearance Tracker · P140015-S020
t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM
Last checked: Nov 20, 2026Latest source record: Aug 25, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Aug 25, 2017
Approved
Time to decision
177 days
Received Mar 1, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P140015-S020
- Device name
- t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM
- Applicant
- Tandem Diabetes Care, Inc.
- Applicant location
- San Diego, CA
- Received
- Mar 1, 2017
- Decided
- Aug 25, 2017
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P140015
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the use of the t:slim X2 Insulin Pump with the Dexcom G5 Mobile CGM and for modifying the indications for use to include pediatric patients ages 6-11 years and replace adjunctive with non-adjunctive CGM use (i.e., replace fingerstick blood glucose testing for diabetes treatment decisions). This device is indicated as follows:The t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM (t:slim X2 System) consists of the t:slim X2 Insulin Pump paired with the Dexcom G5 Mobile Sensor and Transmitter. The t:slim X2 Insulin Pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 Insulin Pump can be used solely for continuous insulin delivery and as part of the t:slim X2 System to receive and display continuous glucose measurements from the Dexcom G5 Mobile Sensor and Transmitter. The t:slim X2 System also includes continuous glucose monitoring (CGM) indicated for the management of diabetes. The Dexcom G5 Mobile CGM is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. The t:slim X2 System aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of the t:slim X2 System results should be based on the trends and patterns seen with several sequential readings over time. The t:slim X2 System is indicated for use in individuals 6 years of age and greater. The t:slim X2 System is intended for single patient use and requires a prescription. The device is indicated for use with NovoLog or Humalog U-100 insulin.
Source documents
Other decisions for Tandem Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Control-IQ+ technology510(k)
K260429 · Decided Apr 24, 2026 · 73 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.